The TIME Trial® Network facilitates rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials

Stephanie O'Leary
Megan Shulman
Kevin Ritt
Meghan Degele
Ewelina Protomastro

See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications

Part of the Oncology Commons, and the Pharmacy and Pharmaceutical Sciences Commons

O'Leary, Stephanie; Shulman, Megan; Ritt, Kevin; Degele, Meghan; Protomastro, Ewelina; Clauson, Jennifer; Franzen, Amy; Anderson, Ian Churchill; Barve, Minal A.; Oubre, David N.; Priego, Victor; Saverimuthu, Angela; Senecal, Francis Mark; Vaddepally, Raju Kumar; Blackwell, Kimberly L.; and Cooney, Matthew M., "The TIME Trial® Network facilitates rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials" (2021). Articles, Abstracts, and Reports. 4801.
https://digitalcommons.psjhealth.org/publications/4801

This Presentation is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Articles, Abstracts, and Reports by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact digitalcommons@providence.org.
Authors
Stephanie O'Leary, Megan Shulman, Kevin Ritt, Meghan Degele, Ewelina Protomastro, Jennifer Clauson, Amy Franzen, Ian Churchill Anderson, Minal A. Barve, David N. Oubre, Victor Priego, Angela Saverimuthu, Francis Mark Senecal, Raju Kumar Vaddepally, Kimberly L. Blackwell, and Matthew M. Cooney
INTRODUCTION

Clinical trials with molecular targets present unique barriers to patients, trial sites, and sponsors. Such barriers can limit access for patients, slow the pace of trial enrollment, and delay the development of new therapeutic options.

The TIME Trial Program was designed to activate clinical trials rapidly on behalf of patients. This just-in-time rapid activation program utilizes proprietary pre-screening technology and a nationwide network of research sites and pharmaceutical sponsors to identify and enroll specific patient populations.

RESULTS

Table 1. Activation Activities and Timelines

<table>
<thead>
<tr>
<th>Timeline</th>
<th>Minimum</th>
<th>Average</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB Submission to Approval</td>
<td>Same Day</td>
<td>2.4 Days</td>
</tr>
<tr>
<td>Activation Initiated to Fully Executed Contract</td>
<td>2 Days</td>
<td>5 Days</td>
</tr>
<tr>
<td>Activation Initiated to Activation Completed</td>
<td>2 Days</td>
<td>8.5 Days</td>
</tr>
<tr>
<td>Site Activated to Patient Consented</td>
<td>Same Day</td>
<td>4 Days</td>
</tr>
<tr>
<td>Patient Consent to First Dose</td>
<td>Same Day</td>
<td>7.2 Days</td>
</tr>
</tbody>
</table>

Timelines are represented in business days.

The TIME Trial® Network facilitates rapid clinical trial activation, patient screening, and enrollment in molecularly targeted trials

The average time from activation to patient consent was 4 days, with 50% of patients consenting within 1 day.

The timeline from patient consent to first dose was completed in an average of 7.2 days.